PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial studies the side effects of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in treating patients with ovarian, uterine, appendiceal, stomach (gastric), or colorectal cancer that has spread to the lining of the abdominal cavity (peritoneal carcinomatosis). Chemotherapy drugs, such as cisplatin, doxorubicin, oxaliplatin, leucovorin, fluorouracil, mitomycin, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. PIPAC is a minimally invasive procedure that involves the administration of intraperitoneal chemotherapy. The study device consists of a nebulizer (a device that turns liquids into a fine mist), which is connected to a high-pressure injector, and inserted into the abdomen (part of the body that contains the digestive organs) during a laparoscopic procedure (a surgery using small incisions to introduce air and to insert a camera and other instruments in the abdominal cavity for diagnosis and/or to perform routine surgical procedures). Pressurization of the liquid chemotherapy through the study device results in aerosolization (a fine mist or spray) of the chemotherapy intra-abdominally (into the abdomen). Giving chemotherapy through PIPAC may reduce the amount of chemotherapy needed to achieve acceptable drug concentration, and therefore potentially reduces side effects and toxicities.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak jajnika, macicy, żołądka, wyrostka lub jelita grubego rozprzestrzeniający się w brzuchu
- •Wcześniejsza chemioterapia w brzuchu jest dozwolona
- •Ogólny stan zdrowia pacjenta pozwala na uczestnictwo (ECOG 0-2)
- •Wystarczająca liczba białych ciałek krwi (neutrocyty >= 1500/mm³)
- •Wystarczająca liczba płytek krwi (>= 100 000/mm³)
- •Hemoglobina >= 9 g/dl
- •Wątroba i nerki pracują prawidłowo (określone wartości badań krwi)
- •Brak przeciwwskazań do laparoskopii (małej operacji)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
City of Hope Medical Center
Duarte, United States
Mayo Clinic in Florida
Jacksonville, United States
Northwell Health Cancer Institute at Huntington
Greenlawn, United States
Trial contact
Thanh H. Dellinger
Thanh H. Dellinger
PRINCIPAL_INVESTIGATOR
Richard L. Whelan
Richard L. Whelan
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.